Recursion Pharmaceuticals Inc. (RXRX) is scheduled to present new preliminary data from its ongoing TUPELO study during the 2025 Digestive Disease Week meeting on May 4, 2025.
TUPELO is a phase Ib/II clinical trial evaluating the safety and preliminary activity of the company's investigational drug REC-4881 for the treatment of familial adenomatous polyposis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com